Lumida
/ATYR
⌘K
aTyr Pharma Inc

aTyr Pharma Inc

ATYR
$0.51USD-1.18%-0.01 today

MARKET CAP

50.0M

P/E (TTM)

FWD P/E

DAY RANGE

$0 – $1

52W RANGE

$0
$7

AI Summary

Stalk
Buy NowMedium

ATYR is forming an early Stage 1 consolidation near multi-year lows with valuations at the lower bound, and mean reversion is permitted. The 9/21 EMAs have flattened and now support price on shallow pullbacks, with no exhaustion signals visible. Price is holding in the lower half of the base, offering a favorable entry around the EMA cluster within the consolidation band. Under a speculative strategy, buying these pullbacks now aligns with upside breakout potential.

  • Loss per share narrowed to $0.11 vs $0.16 estimate.
  • Median $3.00 price target implies ~366% upside.
  • Negative earnings yield and profitability raise red flags.
Full analysis →
Insider Trades6 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Feb 4, 2026SellATYRNancy DenyesGeneral Counsel1,118$0.98$50.0M-93.01%+29.06%$1.1K-3.26%Buy Now
Feb 4, 2026SellATYRJill Marie BroadfootChief Financial Officer1,558$0.98$50.0M-93.01%+29.06%$1.5K-4.01%Buy Now
Feb 4, 2026SellATYRSanjay ShuklaPresident and CEO3,745$0.98$50.0M-93.01%+29.06%$3.7K-2.38%Buy Now
Feb 4, 2025SellATYRNancy DenyesGeneral Counsel899$3.78$50.0M-93.01%+29.06%$3.4K-2.98%Buy Now
Feb 4, 2025SellATYRJill Marie BroadfootChief Financial Officer1,254$3.78$50.0M-93.01%+29.06%$4.7K-3.41%Buy Now
Jun 5, 2024BuyATYRNancy DenyesGeneral Counsel5,000$1.86$50.0M-93.01%+29.06%$9.3K+28.96%Buy Now